Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
Identifieur interne : 001E39 ( PascalFrancis/Curation ); précédent : 001E38; suivant : 001E40Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
Auteurs : Gianluca Severi [Australie] ; Howard A. Morris [Australie] ; Robert J. Maclnnis [Australie] ; Dallas R. English [Australie] ; Wayne D. Tilley [Australie] ; John L. Hopper [Australie] ; Peter Boyle [France] ; Graham G. Giles [Australie]Source :
- Cancer epidemiology, biomarkers & prevention [ 1055-9965 ] ; 2006.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
Abstract
Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I (IGF-I) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 (IGFBP-3) and prostate cancer risk, a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer. We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma samples collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean of 8.7 years follow-up and a randomly sampled subcohort of 1,826 men. The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption. The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 (all odds ratios are between 0.82 and 1.08; Ptrend ≥ 0.2), whereas the risk increased with baseline levels of IGFBP-3 (Ptrend = 0.008), the hazard ratio (HR) associated with a doubling of the concentration of IGFBP-3 being 1.70 (95% confidence interval, 1.15-2.52). The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 (95% confidence interval, 1.11-2.00). The HRs did not differ by tumor aggressiveness or age at onset (all Ps ≥ 0.4). In our study, high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer.
| pA |
|
|---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :004256
Links to Exploration step
Pascal:06-0385763Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer</title><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Morris, Howard A" sort="Morris, Howard A" uniqKey="Morris H" first="Howard A." last="Morris">Howard A. Morris</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hanson Institute, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Maclnnis, Robert J" sort="Maclnnis, Robert J" uniqKey="Maclnnis R" first="Robert J." last="Maclnnis">Robert J. Maclnnis</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="English, Dallas R" sort="English, Dallas R" uniqKey="English D" first="Dallas R." last="English">Dallas R. English</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Tilley, Wayne D" sort="Tilley, Wayne D" uniqKey="Tilley W" first="Wayne D." last="Tilley">Wayne D. Tilley</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hanson Institute, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Hopper, John L" sort="Hopper, John L" uniqKey="Hopper J" first="John L." last="Hopper">John L. Hopper</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Boyle, Peter" sort="Boyle, Peter" uniqKey="Boyle P" first="Peter" last="Boyle">Peter Boyle</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>IARC</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Giles, Graham G" sort="Giles, Graham G" uniqKey="Giles G" first="Graham G." last="Giles">Graham G. Giles</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0385763</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0385763 INIST</idno><idno type="RBID">Pascal:06-0385763</idno><idno type="wicri:Area/PascalFrancis/Corpus">004256</idno><idno type="wicri:Area/PascalFrancis/Curation">001E39</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer</title><author><name sortKey="Severi, Gianluca" sort="Severi, Gianluca" uniqKey="Severi G" first="Gianluca" last="Severi">Gianluca Severi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Morris, Howard A" sort="Morris, Howard A" uniqKey="Morris H" first="Howard A." last="Morris">Howard A. Morris</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hanson Institute, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Maclnnis, Robert J" sort="Maclnnis, Robert J" uniqKey="Maclnnis R" first="Robert J." last="Maclnnis">Robert J. Maclnnis</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="English, Dallas R" sort="English, Dallas R" uniqKey="English D" first="Dallas R." last="English">Dallas R. English</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Tilley, Wayne D" sort="Tilley, Wayne D" uniqKey="Tilley W" first="Wayne D." last="Tilley">Wayne D. Tilley</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hanson Institute, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Hopper, John L" sort="Hopper, John L" uniqKey="Hopper J" first="John L." last="Hopper">John L. Hopper</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author><author><name sortKey="Boyle, Peter" sort="Boyle, Peter" uniqKey="Boyle P" first="Peter" last="Boyle">Peter Boyle</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>IARC</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14><country>France</country></affiliation></author><author><name sortKey="Giles, Graham G" sort="Giles, Graham G" uniqKey="Giles G" first="Graham G." last="Giles">Graham G. Giles</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>Australie</country></affiliation></author></analytic><series><title level="j" type="main">Cancer epidemiology, biomarkers & prevention</title><title level="j" type="abbreviated">Cancer epidemiol. biomark. prev.</title><idno type="ISSN">1055-9965</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Cancer epidemiology, biomarkers & prevention</title><title level="j" type="abbreviated">Cancer epidemiol. biomark. prev.</title><idno type="ISSN">1055-9965</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Australia</term><term>Blood</term><term>Cancerology</term><term>Cohort study</term><term>Epidemiology</term><term>Human</term><term>Insulin like growth factor 1</term><term>Insulin-like growth factor binding protein-3</term><term>Nephrology</term><term>Prostate cancer</term><term>Risk factor</term><term>Urology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Facteur croissance IGF1</term><term>Sang</term><term>Facteur risque</term><term>Cancer prostate</term><term>Epidémiologie</term><term>Etude cohorte</term><term>Cancérologie</term><term>Australie</term><term>Homme</term><term>Urologie</term><term>Protéine liaison IGFBP3</term><term>Néphrologie</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I (IGF-I) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 (IGFBP-3) and prostate cancer risk, a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer. We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma samples collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean of 8.7 years follow-up and a randomly sampled subcohort of 1,826 men. The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption. The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 (all odds ratios are between 0.82 and 1.08; P<sub>trend</sub> ≥ 0.2), whereas the risk increased with baseline levels of IGFBP-3 (P<sub>trend</sub> = 0.008), the hazard ratio (HR) associated with a doubling of the concentration of IGFBP-3 being 1.70 (95% confidence interval, 1.15-2.52). The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 (95% confidence interval, 1.11-2.00). The HRs did not differ by tumor aggressiveness or age at onset (all Ps ≥ 0.4). In our study, high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1055-9965</s0></fA01><fA03 i2="1"><s0>Cancer epidemiol. biomark. prev.</s0></fA03><fA05><s2>15</s2></fA05><fA06><s2>6</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer</s1></fA08><fA11 i1="01" i2="1"><s1>SEVERI (Gianluca)</s1></fA11><fA11 i1="02" i2="1"><s1>MORRIS (Howard A.)</s1></fA11><fA11 i1="03" i2="1"><s1>MACLNNIS (Robert J.)</s1></fA11><fA11 i1="04" i2="1"><s1>ENGLISH (Dallas R.)</s1></fA11><fA11 i1="05" i2="1"><s1>TILLEY (Wayne D.)</s1></fA11><fA11 i1="06" i2="1"><s1>HOPPER (John L.)</s1></fA11><fA11 i1="07" i2="1"><s1>BOYLE (Peter)</s1></fA11><fA11 i1="08" i2="1"><s1>GILES (Graham G.)</s1></fA11><fA14 i1="01"><s1>Cancer Epidemiology Centre, The Cancer Council Victoria</s1><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="02"><s1>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne</s1><s2>Melbourne, Victoria</s2><s3>AUS</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>8 aut.</sZ></fA14><fA14 i1="03"><s1>Hanson Institute, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></fA14><fA14 i1="04"><s1>Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide</s1><s2>Adelaide, South Australia</s2><s3>AUS</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>IARC</s1><s2>Lyon</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA20><s1>1137-1141</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26637</s2><s5>354000138902990110</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>31 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>06-0385763</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Cancer epidemiology, biomarkers & prevention</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Some recent epidemiologic studies have failed to confirm positive associations between insulin-like growth factor-I (IGF-I) and the risk of prostate cancer observed in earlier studies but have reported suggestive evidence for a positive association between IGF-binding protein-3 (IGFBP-3) and prostate cancer risk, a result contradicting the earlier assumption that high levels of IGFBP-3 would be protective against prostate cancer. We tested the association between IGF-I and IGFBP-3 and prostate cancer risk by measuring the two peptides in plasma samples collected at baseline in a prospective cohort study of 17,049 men. We used a case-cohort design, including 524 cases diagnosed during a mean of 8.7 years follow-up and a randomly sampled subcohort of 1,826 men. The association between each peptide level and prostate cancer risk was tested using Cox models adjusted for country of birth and alcohol consumption. The risk of prostate cancer was not associated with baseline levels of IGF-I or the molar ratio IGF-I/IGFBP-3 (all odds ratios are between 0.82 and 1.08; P<sub>trend</sub> ≥ 0.2), whereas the risk increased with baseline levels of IGFBP-3 (P<sub>trend</sub> = 0.008), the hazard ratio (HR) associated with a doubling of the concentration of IGFBP-3 being 1.70 (95% confidence interval, 1.15-2.52). The HR for quartile 4 relative to quartile 1 of IGFBP-3 was 1.49 (95% confidence interval, 1.11-2.00). The HRs did not differ by tumor aggressiveness or age at onset (all Ps ≥ 0.4). In our study, high levels of IGFBP-3 but not IGF-I were associated with an increased risk of prostate cancer.</s0></fC01><fC02 i1="01" i2="X"><s0>002B04</s0></fC02><fC02 i1="02" i2="X"><s0>002B14D02</s0></fC02><fC02 i1="03" i2="X"><s0>235</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Facteur croissance IGF1</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Insulin like growth factor 1</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Factor crecimiento IGF1</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Sang</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Blood</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Sangre</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Facteur risque</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Risk factor</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Factor riesgo</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Cancer prostate</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Prostate cancer</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Cáncer de la próstata</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Epidémiologie</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Epidemiology</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Epidemiología</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Etude cohorte</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Cohort study</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Estudio cohorte</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Cancérologie</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Cancerology</s0><s5>08</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Cancerología</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Australie</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Australia</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Australia</s0><s2>NG</s2><s5>09</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Human</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Urologie</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Urology</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Urología</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Protéine liaison IGFBP3</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Insulin-like growth factor binding protein-3</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Proteína enlace IGFBP3</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Néphrologie</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Nephrology</s0><s4>CD</s4><s5>97</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Nefrología</s0><s4>CD</s4><s5>97</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Océanie</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Oceania</s0><s2>NG</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Oceania</s0><s2>NG</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Appareil génital mâle pathologie</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>37</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Appareil urinaire pathologie</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Urinary system disease</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Aparato urinario patología</s0><s5>38</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Tumeur maligne</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Malignant tumor</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Tumor maligno</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Prostate pathologie</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0><s5>40</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Santé publique</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Public health</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Salud pública</s0><s5>41</s5></fC07><fN21><s1>254</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E39 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001E39 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PascalFrancis
|étape= Curation
|type= RBID
|clé= Pascal:06-0385763
|texte= Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer
}}
| This area was generated with Dilib version V0.6.33. |  |